Lyell Immunopharma, Inc. (NASDAQ: LYEL)

Lyell Immunopharma, Inc., or LYEL, operates in the biotechnology industry, specifically as a clinical-stage cell therapy company. The company's primary focus is on advancing a pipeline of product candidates for patients with solid tumors utilizing its proprietary ex vivo genetic and epigenetic T-cell reprogramming technologies.

Lyell's main business activities involve clinical development of T-cell therapies, conducting research and development, acquiring technology, entering into strategic collaboration and license agreements, enabling and executing manufacturing activities in support of its product candidate development efforts, organizing and staffing the company, business planning, establishing its intellectual property portfolio, making regulatory submissions, executing clinical trials, raising capital, and providing general and administrative support for these activities.

The company generates revenue through the development and commercialization of its product candidates, including LYL797, LYL845, LYL119, and a second-generation TIL product candidate. These product candidates are designed to address large patient populations with unmet needs in solid tumor indications, such as triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC).

LYL797 is a genetically and epigenetically reprogrammed ROR1 CAR T-cell product candidate designed for differentiated potency and durability targeting multiple solid tumor indications. The product candidate incorporates the company's c-Jun and Epi-R technologies and is manufactured using its proprietary Epi-R technology. LYL797 is being evaluated in a Phase 1 clinical trial in patients with relapsed/refractory TNBC or NSCLC.

LYL845 is a TIL product candidate that incorporates the company's Epi-R technology and is being evaluated in a Phase 1 clinical trial in patients with advanced melanoma, relapsed/refractory NSCLC, or colorectal cancer (CRC).

LYL119 is a CAR T-cell product candidate that incorporates the company's c-Jun, NR4A3, Epi-R, and Stim-R technologies and is currently in preclinical development.

Lyell's competitive advantages include its proprietary ex vivo genetic and epigenetic T-cell reprogramming technologies, which address the primary barriers to effective cell therapy in solid tumors: T-cell exhaustion and lack of durable stemness. The company's technologies can be applied in a target-agnostic manner to multiple T-cell modalities, including CAR, TIL, and TCR therapies.

As Lyell does not have any products approved for sale, it does not have any customers. The company is focused on advancing its product candidates through clinical trials and regulatory approvals.

In terms of its product portfolio, Lyell has built and operates a wholly-owned manufacturing facility, LyFE Manufacturing Center, which is producing cell product for its clinical trials. The company is also advancing its Epi-R P2 manufacturing process, which is designed to shorten TIL manufacturing time without impacting cell number and phenotype.

Lyell has developed and secured intellectual property, including know-how, through its internal research efforts, licensing agreements, and collaborations. The company rigorously analyzes, files, and protects its intellectual property in an ongoing manner.

Lyell considers various ways to collaborate with external partners, including strategic partnerships and collaborations to maximize the potential of its technologies and products. The company is open to partnering programs, indications, or geographies with pharmaceutical or biotechnology companies for development and/or commercialization.